Back to results
US 12,421,293 B2Granted
Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases
AssigneeJura Bio, Inc.
InventorsJulie Norville, Elizabeth Wood
Life of this patent
Estimating the term…
Abstract
Major histocompatibility complex-based chimeric receptors (MHC-CAR) for use in targeting autoreactive immune cells. Also provided herewith are genetically engineered immune cells expressing the MHC-CAR for use in treating autoimmune diseases such as multiple sclerosis.
Claims17
A major histocompatibility complex (MHC)-based chimeric receptor, comprising:
- (i) an extracellular domain of an MHC molecule conjugated to an antigenic peptide from an antigen involved in an autoimmune disease;
- and
- (ii) a cytoplasmic signaling domain, at least one co-stimulatory domain, or a combination thereof;
- wherein the MHC molecule is a class I MHC;
- and
- wherein the extracellular domain of the chimeric receptor comprises an extracellular domain of the alpha chain of the class I MHC, which is fused to the antigenic peptide.
3 more elements
A genetically modified immune cell, which expresses an MHC-based chimeric receptor;
- which comprises:
- (i) an extracellular domain of an MHC molecule conjugated to an antigenic peptide from an antigen involved in an autoimmune disease;
- and
- (ii) a cytoplasmic signaling domain, at least one co-stimulatory domain, or a combination thereof;
- wherein the MHC molecule is a class I MHC, and
- wherein the extracellular domain of the chimeric receptor comprises an extracellular domain of the alpha chain of the class I MHC, which is fused to the antigenic peptide.
3 more elements
Dependencies are inferred from the claim text.